title: Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus.
abstract: OBJECTIVE
  To evaluate the efficacy of long-term thalidomide treatment in cutaneous lesions of systemic lupus erythematosus (SLE), not responsive to conventional therapy.
  
  
  METHODS
  Were selected 18 SLE patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photoprotectors and low doses prednisone and who presented good response to thalidomide but relapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose (25-100 mg/day) for a minimum of 6 months.
  
  
  RESULTS
  Eighteen patients (16 females) with mean age of 34.2 yo (16-57 y.o.) received thalidomide for 6-21 months (mean 8.5 m). The mean dose of prednisone at beginning of study was 38.3 mg/d and at the end was 9.7 mg/d (p < 0.05). Complete remission of cutaneous lesions was observed in thirteen patients (72%) and partial remission in five (28%). Side effects observed were: drowsiness in eight patients, intestinal constipation in 5, transient oliguria in 1, paresthesia of hand with normal electromyography in another one. All side effects disappeared with reduction of thalidomide dose and no patient needed to stop treatment owing to side effect.
  
  
  CONCLUSIONS
  Thalidomide is a good alternative therapy to SLE patients with refractory cutaneous lesions and without any risk of pregnancy.
authors.affiliation: Department of Medicine, Universidade Federal de São Paulo, Brazil.
authors.forename: E I
authors.initials: EI
authors.lastname: Sato
authors.forename: L S
authors.initials: LS
authors.lastname: Assis
authors.forename: V P
authors.initials: VP
authors.lastname: Lourenzi
authors.forename: L E
authors.initials: LE
authors.lastname: Andrade
mesh_terms: D000293:Adolescent; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology*; D013792:Thalidomide / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide; D011241:Prednisone